Rare Predicted Loss-of-function Variants of Type I IFN Immunity Genes Are Associated with Life-threatening COVID-19

Background: We previously reported that impaired type I IFN activity, due to inborn errors of TLR3- and TLR7-dependent type I interferon (IFN) immunity or to autoantibodies against type I IFN, account for 15-20% of cases of life-threatening COVID-19 in unvaccinated patients. Therefore, the determinants of life-threatening COVID-19 remain to be identified in ~ 80% of cases.

Methods: We report here a genome-wide rare variant burden association analysis in 3269 unvaccinated patients with life-threatening COVID-19, and 1373 unvaccinated SARS-CoV-2-infected individuals without pneumonia. Among the 928 patients tested for autoantibodies against type I IFN, a quarter (234) were positive and were excluded.

Results: No gene reached genome-wide significance. Under a recessive model, the most significant gene with at-risk variants was TLR7, with an OR of 27.68 (95%CI 1.5-528.7, P = 1.1 × 10) for biochemically loss-of-function (bLOF) variants. We replicated the enrichment in rare predicted LOF (pLOF) variants at 13 influenza susceptibility loci involved in TLR3-dependent type I IFN immunity (OR = 3.70[95%CI 1.3-8.2], P = 2.1 × 10). This enrichment was further strengthened by (1) adding the recently reported TYK2 and TLR7 COVID-19 loci, particularly under a recessive model (OR = 19.65[95%CI 2.1-2635.4], P = 3.4 × 10), and (2) considering as pLOF branchpoint variants with potentially strong impacts on splicing among the 15 loci (OR = 4.40[9%CI 2.3-8.4], P = 7.7 × 10). Finally, the patients with pLOF/bLOF variants at these 15 loci were significantly younger (mean age [SD] = 43.3 [20.3] years) than the other patients (56.0 [17.3] years; P = 1.68 × 10).

Conclusions: Rare variants of TLR3- and TLR7-dependent type I IFN immunity genes can underlie life-threatening COVID-19, particularly with recessive inheritance, in patients under 60 years old.

Citing Articles

No Association Between HLH-associated Gene Variants and Life-Threatening COVID-19.

Covill L, Cobat A, Zhang Q, Bryceson Y J Clin Immunol. 2025; 45(1):80.

PMID: 40067421 PMC: 11897064. DOI: 10.1007/s10875-025-01870-6.

Genetic and Epigenetic Intersections in COVID-19-Associated Cardiovascular Disease: Emerging Insights and Future Directions.

Sabit H, Arneth B, Altrawy A, Ghazy A, Abdelazeem R, Adel A Biomedicines. 2025; 13(2).

PMID: 40002898 PMC: 11852909. DOI: 10.3390/biomedicines13020485.

Proteomic Analyses in COVID-19-Associated Secondary Hemophagocytic Lymphohistiocytosis.

Canny S, Stanaway I, Holton S, Mitchem M, ORourke A, Pribitzer S Crit Care Explor. 2025; 7(2):e1203.

PMID: 39888602 PMC: 11789895. DOI: 10.1097/CCE.0000000000001203.

Genetic diversity of the immunoglobulin heavy chain locus in cohorts of patients affected with SARS-CoV-2.

Malaspina P, Jodice C, Ciminelli B, Biancolella M, Colona V, Latini A Hum Genomics. 2025; 19(1):7.

PMID: 39885568 PMC: 11780896. DOI: 10.1186/s40246-025-00719-8.

Neutrophils restricted contribution of genetic variants to COVID-19 severity.

Laffranchi M, Paraboschi E, Bianchetto-Aguilera F, Tamassia N, Gasperini S, Gardiman E Heliyon. 2025; 11(1):e41267.

PMID: 39811276 PMC: 11731188. DOI: 10.1016/j.heliyon.2024.e41267.

References

Zhang Q, Bastard P, Cobat A, Casanova J . Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature. 2022; 603(7902):587-598. PMC: 8957595. DOI: 10.1038/s41586-022-04447-0. View

ODriscoll M, Ribeiro Dos Santos G, Wang L, Cummings D, Azman A, Paireau J . Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2020; 590(7844):140-145. DOI: 10.1038/s41586-020-2918-0. View

Bennett T, Moffitt R, Hajagos J, Amor B, Anand A, Bissell M . Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative. JAMA Netw Open. 2021; 4(7):e2116901. PMC: 8278272. DOI: 10.1001/jamanetworkopen.2021.16901. View

Takahashi T, Ellingson M, Wong P, Israelow B, Lucas C, Klein J . Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020; 588(7837):315-320. PMC: 7725931. DOI: 10.1038/s41586-020-2700-3. View

Pairo-Castineira E, Clohisey S, Klaric L, Bretherick A, Rawlik K, Pasko D . Genetic mechanisms of critical illness in COVID-19. Nature. 2020; 591(7848):92-98. DOI: 10.1038/s41586-020-03065-y. View

Zeberg H, Paabo S . The major genetic risk factor for severe COVID-19 is inherited from Neanderthals. Nature. 2020; 587(7835):610-612. DOI: 10.1038/s41586-020-2818-3. View

Kousathanas A, Pairo-Castineira E, Rawlik K, Stuckey A, Odhams C, Walker S . Whole-genome sequencing reveals host factors underlying critical COVID-19. Nature. 2022; 607(7917):97-103. PMC: 9259496. DOI: 10.1038/s41586-022-04576-6. View

Namkoong H, Edahiro R, Takano T, Nishihara H, Shirai Y, Sonehara K . DOCK2 is involved in the host genetics and biology of severe COVID-19. Nature. 2022; 609(7928):754-760. PMC: 9492544. DOI: 10.1038/s41586-022-05163-5. View

Casanova J, Su H . A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection. Cell. 2020; 181(6):1194-1199. PMC: 7218368. DOI: 10.1016/j.cell.2020.05.016. View

10.

Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J . Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020; 370(6515). PMC: 7857407. DOI: 10.1126/science.abd4570. View

11.

Abolhassani H, Landegren N, Bastard P, Materna M, Modaresi M, Du L . Inherited IFNAR1 Deficiency in a Child with Both Critical COVID-19 Pneumonia and Multisystem Inflammatory Syndrome. J Clin Immunol. 2022; 42(3):471-483. PMC: 8798309. DOI: 10.1007/s10875-022-01215-7. View

12.

Khanmohammadi S, Rezaei N, Khazaei M, Shirkani A . A Case of Autosomal Recessive Interferon Alpha/Beta Receptor Alpha Chain (IFNAR1) Deficiency with Severe COVID-19. J Clin Immunol. 2021; 42(1):19-24. PMC: 8553400. DOI: 10.1007/s10875-021-01166-5. View

13.

Schmidt A, Peters S, Knaus A, Sabir H, Hamsen F, Maj C . TBK1 and TNFRSF13B mutations and an autoinflammatory disease in a child with lethal COVID-19. NPJ Genom Med. 2021; 6(1):55. PMC: 8249618. DOI: 10.1038/s41525-021-00220-w. View

14.

Zhang Q, Matuozzo D, Le Pen J, Lee D, Moens L, Asano T . Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. J Exp Med. 2022; 219(8). PMC: 9206114. DOI: 10.1084/jem.20220131. View

15.

Butler-Laporte G, Povysil G, Kosmicki J, Cirulli E, Drivas T, Furini S . Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative. PLoS Genet. 2022; 18(11):e1010367. PMC: 9632827. DOI: 10.1371/journal.pgen.1010367. View

16.

Kosmicki J, Horowitz J, Banerjee N, Lanche R, Marcketta A, Maxwell E . Pan-ancestry exome-wide association analyses of COVID-19 outcomes in 586,157 individuals. Am J Hum Genet. 2021; 108(7):1350-1355. PMC: 8173480. DOI: 10.1016/j.ajhg.2021.05.017. View

17.

Bastard P, Rosen L, Zhang Q, Michailidis E, Hoffmann H, Zhang Y . Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020; 370(6515). PMC: 7857397. DOI: 10.1126/science.abd4585. View

18.

Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J . Autoantibodies neutralizing type I IFNs are present in 4% of uninfected individuals over 70 years old and account for 20% of COVID-19 deaths. Sci Immunol. 2021; 6(62. PMC: 8521484. DOI: 10.1126/sciimmunol.abl4340. View

19.

Casanova J, Abel L . From rare disorders of immunity to common determinants of infection: Following the mechanistic thread. Cell. 2022; 185(17):3086-3103. PMC: 9386946. DOI: 10.1016/j.cell.2022.07.004. View

20.

Asano T, Boisson B, Onodi F, Matuozzo D, Moncada-Velez M, Maglorius Renkilaraj M . X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci Immunol. 2021; 6(62). PMC: 8532080. DOI: 10.1126/sciimmunol.abl4348. View